Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

Scientists at Novo Nordisk in Denmark have applied flow chemistry to enhance the cleavage of oligonucleotides.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

The bicentenary of St Patrick's Church, Dysart, will be marked in late August with Dr Kevin Doran, Bishop of Elphin and ...

Camilla Sylvest has moved on from Novo Nordisk after 28 years with the Danish pharma, including more than seven years as EVP ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

This technological excellence is mirrored in Athlone’s thriving life sciences sector. Noteworthy contributors in these sectors include 3M, Teleflex, Almac and Medtronic alongside Novo Nordisk which ...

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders. Novo Nordisk is expanding its obesity drug ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...